FBI director could appear before lawmakers to explain

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
FBI director could appear before lawmakers to explain Clinton decision

FBI Director James Comey took no questions after his bombshell announcement Tuesday that he would not recommend criminal charges against Hillary Clinton over her private email system, but he - and his boss - may soon answer to lawmakers.

Comey may shed more light on his decision-making process when called before lawmakers. (Associated Press)

"The job of the FBI is to provide the fact pattern to the Justice Department and not make the political calculation that this is what a reasonable prosecutor would do. That's not the job of the FBI," Chaffetz, who chairs the Oversight Committee, told Fox News host Bret Baier Tuesday night.

Fox News has learned both Lynch and Comey may appear at House hearings on the email case in the near future. Comey, who Fox News has learned would appear willingly, likely won't appear before the committee until September, when it returns from its upcoming recess.

Lynch was already slated to testify next Tuesday at an oversight hearing where Fox News has learned she will be questioned about the email investigation, and possibly her secret meeting with former President Bill Clinton just days before her department dropped the email case against the former first lady.
2016 Election Headquarters

The latest headlines on the 2016 elections from the biggest name in politics.
See Latest Coverage →

Comey's decision was seen in many quarters as a punt. By branding Clinton's use of unauthorized servers to send and receive sensitive -- and in some cases top secret -- information as "extremely careless," Comey gave Clinton's critics plenty of ammunition.

By stopping short of referring the results of his bureau's year-long probe to the Attorney General to pursue an indictment, Comey may have removed the biggest obstacle in Clinton's path to the White House.

“Our judgment is that no reasonable prosecutor would bring such a case,” Comey said.

The development leaves it to the voters -- especially those who remain undecided -- to decide whether they believe Clinton did nothing criminal in her handling of emails while secretary of state — or whether it just becomes another questionable chapter in the Clinton political saga that has spanned a quarter century that both she and her husband seem able to survive.

Johnson, who chairs the Homeland Security and Government Affairs Committee, fired off a letter to Comey hours after the 13-minute news conference demanding answers to a series of questions. Among them, Johnson asked how many agents worked on the case, how much taxpayer money was spent on it and, perhaps more significantly, how Comey arrived at his conclusion.

“If the evidence that the FBI collected about Secretary Clinton’s use of a private email account and server did not constitute gross negligence, what set of facts would cause the FBI to recommend criminal charges under the gross negligence standard?” Johnson wrote.

Comey said Clinton was "extremely careless" with sensitive emails. (Associated Press)

Goodlatte, chairman of the House Judiciary Committee, also wrote Comey and detailed several other cases in which lower-ranking government employees have been prosecuted for mishandling sensitive information.

"I find the timing and manner of your announcement uniquely troubling in light of last week's secret meeting between Attorney General Loretta Lynch and former President Bill Clinton," Goodlatte wrote.

Goodlatte and Johnson both noted that one of the statutes Clinton was suspected of violating does not require criminal intent. The law is written to impose an obligation on government employees to safeguard sensitive documents, and thus requires a finding of gross negiligence.

Comey said 110 emails in 52 email chains discovered on Clinton’s unauthorized server were classified at the time they were sent or received, including some that were “top secret.”

Trump is already using Comey's words to blast Clinton, even as he faults the FBI director for not pursuing the case.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 295

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 143

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 132

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 143

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 214

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 160

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 185

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 70

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 270

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading

Top 5 Most Recently Viewed Articles

WTW Welcomes Dale Porfilio as Director for Business Development

Updated Category News Views 138

WTW Appoints New Leader for Business Development In a significant move to enhance its operations, WTW (NASDAQ: WTW) has announced the appointment of Dale Porfilio as Senior Director and Head of Personal and Commercial Lines Business Development within its Insurance Consulting & Technology (ICT) segment. A Seasoned Professional Joins WTW Porfilio brings a wealth of...

Continue Reading
Jorgen Vig Knudstorp's Bold Stock Purchase at Starbucks

Updated Category News Views 74

Jorgen Vig Knudstorp Invests in Starbucks, Showing Strong Confidence Recently, Jorgen Vig Knudstorp, a director at Starbucks Corp (NASDAQ:SBUX), made a significant move by buying shares of the company. This act signals a firm vote of confidence in the future of the beloved coffee chain. When insiders make such investments, it often grabs the attention of other investors...

Continue Reading
Understanding Inventiva's Latest Half-Year Report and Future Plans

Updated Category News Views 65

Inventiva Files its 2024 Half-Year Report Inventiva, a prominent clinical-stage biopharmaceutical company, is making significant strides in the healthcare sector. Focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis, commonly known as MASH/NASH, the company recently announced its filing of the 2024 Half-Year Report for the period...

Continue Reading
Analyzing Organon's Upcoming Earnings Announcement and Insights

Updated Category News Views 177

Anticipation Surrounding Organon's Earnings Report Organon (OGN) is on the verge of revealing its quarterly earnings report, a moment eagerly awaited by investors. As preparations finalize for this significant announcement, understanding the forecasted outcomes can guide investor decisions moving forward. Expected Earnings Figures Forecast estimates suggest that Organon...

Continue Reading
Miami Real Estate Trends: A Surge in Older Condo Sales

Updated Category News Views 180

Understanding the Miami-Dade Real Estate Market Miami-Dade County's real estate landscape is shifting, with older condominiums experiencing quicker sales than their newer counterparts. This trend indicates a solid demand for older condos, highlighting their appeal in a market where affordable housing options continue to thrive. Statistical data reveal that older...

Continue Reading